MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze ABSI →
    • FindStock Picks / Stock Screener
    • Value · ABSIIntrinsic Value Calculator
    • Invest · ABSIInvestment Case
    • Hold · ABSI5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ABSI stock logo

ABSI

Absci Corporation

$8.25
-0.63
 (-7.09%)
Exchange:  NASDAQ
Market Cap:  1.416B
Shares Outstanding:  92.25M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  BiotechnologyView industry performance
   
CEO:  Sean McClain
Full Time Employees:  140
Address: 
18105 SE Mill Plain Boulevard
Vancouver
WA
98683
US
Website:  https://www.absci.com
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
ABABSI logoABSIAbsci Corporation1.4B——-52.2%
COCOAG logoCOAGHemab Therapeutics Holdings, Inc. Comm…1.4B——-10.9%
AAAAPG logoAAPGAscentage Pharma Group International1.4B——-48.9%
RARARE logoRAREUltragenyx Pharmaceutical Inc.1.4B——-53.5%
ANANAB logoANABAnaptysBio, Inc.1.4B6.89.247.2%
KLKLRA logoKLRAKailera Therapeutics, Inc.1.5B——-18.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue5,7184,5342,800
Gross Profit-41,849-57,925-8,942
EBITDA-79,681-94,099-103,163
Operating Income-115,515-108,888-124,718
Net Income-110,566-103,106-115,183

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets234,480213,608216,297
Total Liabilities58,30434,47526,848
Total Stockholders Equity176,176179,133189,449
Total Debt15,95710,1055,302
Cash and Cash Equivalents88,55541,21320,025

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-64,635.999-72,402-92,925
Capital Expenditure-860-404-1,107
Free Cash Flow-65,495.999-72,806-94,032
Net Income-110,566-103,106-115,183
Net Change in Cash13,577-31,453-37,136

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)10,454.472Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)359,967.229Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)103,870.200Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)12,271.061Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)22,849.159Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)19,943.045Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-10,065.579Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)404.891Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-2,393.595Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)26,179.491Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)901,409.365Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)260,105.819Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-0.020Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)0Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.070Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)5Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)4Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
5.718M  ?P/S
 (TTM)
: 
1102.57
?Net Income
 (TTM)
: 
-110.566M  ?P/E
 (TTM)
: 
-12.7
?Enterprise Value
 (TTM)
: 
1.617B  ?EV/FCF
 (TTM)
: 
-14.84
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-59.21%  ?ROIC
 (TTM)
: 
-52.24%
?Net Debt
 (TTM)
: 
-130.878M  ?Debt/Equity
 (TTM)
: 
0.01
?P/B
 (TTM)
: 
6.5  ?Current Ratio
 (TTM)
: 
10.63

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
N/AResearch AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates ABSI intrinsic value between $0.66 – $0.66 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate ABSI Intrinsic Value

Common questions about ABSI valuation

Is Absci Corporation (ABSI) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Absci Corporation (ABSI) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ABSI a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ABSI trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ABSI’s P/E ratio?

You can see ABSI’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ABSI?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ABSI a good long-term investment?

Whether ABSI fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Absci Corporation

  • Absci Corporation intrinsic value calculatorEstimate what the business is worth
  • Absci Corporation 5-year outlookWhat has to go right, and what could go wrong
ABSI

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-7.09
MarketSnap

Trading Metrics:

Open: 8.81   Previous Close: 8.88
Day Low: 8.13   Day High: 8.95
Year Low: 2.24   Year High: 12.06
Price Avg 50: 9.34   Price Avg 200: 6.14
Volume: 3.533M   Average Volume: 4.516M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
08-10-2026 04:15
Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX)
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
04-09-2026 03:26
Absci Corporation $ABSI Shares Bought by Bank of America Corp DE
Absci Q2 Earnings Call Highlights
11-08-2026 18:07
Absci Q2 Earnings Call Highlights
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
11-08-2026 14:00
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
02-07-2026 13:01
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to Buy
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program
24-06-2026 09:09
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis Program

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze ABSI →
    • FindStock Picks / Stock Screener
    • Value · ABSIIntrinsic Value Calculator
    • Invest · ABSIInvestment Case
    • Hold · ABSI5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read